ASXL1 and Buschke-Ollendorff syndrome: One intriguing extension from our analysis is the potential to repurpose or harness novel Wnt inhibitors or chromatin modifying drugs to ameliorate the effects of ASXL1 variants in a range of diseases, including BOS and subtypes of AML.